Sun Pharmaceuticals plans to focus on dermatology, post its merger with Ranbaxy Labs, expected to be completed by 2014. The company has lined-up a strategy to make dermatology its biggest segment and expects almost 38-40% of US sales to come from dermatology by FY2018.

Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''For the same, the company plans to ramp up its Dusa facilities in the US. After the merger, the company will generate around USD 800 million from the dermatology segment, which is expected to double, thereby also pushing up the margins. We maintain our neutral on both the stock.''

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.